STOCK TITAN

[Form 4] US Physical Therapy Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share. After the sale he beneficially owns 114,088 shares in total. The filing discloses that 34,098 of those shares were granted as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan, with a detailed vesting schedule listing tranche dates and share counts through March 6, 2029, contingent on continued employment.

Modulo USPH 4: Christopher J. Reading, Presidente e CEO di U S Physical Therapy Inc (USPH), ha riportato una singola operazione il 04/09/2025 consistente nella vendita di 2.000 azioni del capitale sociale della società a 83,53 $ per azione. Dopo la vendita possiede beneficiariamente in totale 114.088 azioni. La comunicazione rivela che 34.098 di queste azioni sono state assegnate come azioni vincolate nell'ambito dell'Amended and Restated 2003 Stock Incentive Plan della società, con un piano di maturazione dettagliato che elenca le tranche e il numero di azioni fino al 6 marzo 2029, condizionato alla permanenza in servizio.

Formulario USPH 4: Christopher J. Reading, presidente y CEO de U S Physical Therapy Inc (USPH), informó una única transacción el 04/09/2025, vendiendo 2.000 acciones del capital común de la emisora a 83,53 $ por acción. Tras la venta posee beneficiariamente un total de 114.088 acciones. La presentación revela que 34.098 de esas acciones fueron otorgadas como acciones restringidas bajo el Amended and Restated 2003 Stock Incentive Plan de la compañía, con un calendario de consolidación detallado que enumera fechas de tramos y cantidades de acciones hasta el 6 de marzo de 2029, sujeto a la continuidad en el empleo.

USPH 양식 4: U S Physical Therapy Inc(USPH)의 회장 겸 CEO인 Christopher J. Reading은 2025년 9월 4일 단일 거래로 발행회사의 보통주 2,000주를 주당 83.53달러에 매각했다고 보고했습니다. 매각 후 그는 총 114,088주를 수익적으로 보유하고 있습니다. 제출서류는 그 중 34,098주가 회사의 Amended and Restated 2003 Stock Incentive Plan에 따른 제한주로 부여되었으며, 계속 고용을 조건으로 2029년 3월 6일까지의 트랜치 날짜와 주식 수를 열거한 상세한 베스팅 일정이 포함되어 있음을 밝히고 있습니다.

Formulaire USPH 4 : Christopher J. Reading, président et directeur général de U S Physical Therapy Inc (USPH), a déclaré une transaction unique le 04/09/2025, vendant 2 000 actions ordinaires de l'émetteur au prix de 83,53 $ par action. Après la vente, il détient bénéficiairement au total 114 088 actions. Le dépôt révèle que 34 098 de ces actions ont été attribuées en tant qu'actions restreintes dans le cadre de l'Amended and Restated 2003 Stock Incentive Plan de la société, avec un calendrier d'acquisition détaillé listant les dates des tranches et le nombre d'actions jusqu'au 6 mars 2029, sous réserve de la poursuite de l'emploi.

USPH Formular 4: Christopher J. Reading, Vorsitzender und CEO von U S Physical Therapy Inc (USPH), meldete am 04.09.2025 eine einzelne Transaktion, bei der er 2.000 Aktien des Stammkapitals des Emittenten zu einem Preis von 83,53 $ pro Aktie verkaufte. Nach dem Verkauf besitzt er wirtschaftlich insgesamt 114.088 Aktien. Die Einreichung gibt an, dass 34.098 dieser Aktien als Restricted Stock im Rahmen des Amended and Restated 2003 Stock Incentive Plan des Unternehmens zugeteilt wurden, mit einem detaillierten Vesting-Plan, der Tranchen-Daten und Aktienzahlen bis zum 6. März 2029 aufführt, vorbehaltlich fortgesetzter Beschäftigung.

Positive
  • Detailed disclosure of restricted stock tranches totaling 34,098 shares with exact vesting dates through March 6, 2029
  • Clear reporting of insider status: Christopher J. Reading is identified as Chairman of the Board and CEO and filed individually
Negative
  • Insider sale of 2,000 shares on 09/04/2025 at $83.53 per share
  • No details in the filing about the purpose of the sale or any Rule 10b5-1 plan designation

Insights

TL;DR: Reporting person sold a small block of shares and retains a substantial position including time‑vested restricted stock.

The Form 4 records a disposition of 2,000 shares at $83.53, reducing the immediate holding but leaving 114,088 shares beneficially owned. The filing clearly itemizes that 34,098 shares are restricted stock with a multi‑year vesting schedule through March 6, 2029, contingent on continued employment. From a disclosure perspective this is routine insider activity: it shows liquidity taken by an executive while maintaining a significant retained stake and scheduled future vesting.

TL;DR: Transaction is a routine insider sale; vesting schedule is explicitly disclosed.

The document provides specific compliance information: the reporting person is both Chairman and CEO and filed as an individual reporting person. The Form 4 includes the transaction code (S) for sale and the remaining beneficial ownership total. It also discloses the number of restricted shares and precise vesting tranches, which aids transparency on potential future insider stock availability. No amendments or additional derivative positions are reported.

Modulo USPH 4: Christopher J. Reading, Presidente e CEO di U S Physical Therapy Inc (USPH), ha riportato una singola operazione il 04/09/2025 consistente nella vendita di 2.000 azioni del capitale sociale della società a 83,53 $ per azione. Dopo la vendita possiede beneficiariamente in totale 114.088 azioni. La comunicazione rivela che 34.098 di queste azioni sono state assegnate come azioni vincolate nell'ambito dell'Amended and Restated 2003 Stock Incentive Plan della società, con un piano di maturazione dettagliato che elenca le tranche e il numero di azioni fino al 6 marzo 2029, condizionato alla permanenza in servizio.

Formulario USPH 4: Christopher J. Reading, presidente y CEO de U S Physical Therapy Inc (USPH), informó una única transacción el 04/09/2025, vendiendo 2.000 acciones del capital común de la emisora a 83,53 $ por acción. Tras la venta posee beneficiariamente un total de 114.088 acciones. La presentación revela que 34.098 de esas acciones fueron otorgadas como acciones restringidas bajo el Amended and Restated 2003 Stock Incentive Plan de la compañía, con un calendario de consolidación detallado que enumera fechas de tramos y cantidades de acciones hasta el 6 de marzo de 2029, sujeto a la continuidad en el empleo.

USPH 양식 4: U S Physical Therapy Inc(USPH)의 회장 겸 CEO인 Christopher J. Reading은 2025년 9월 4일 단일 거래로 발행회사의 보통주 2,000주를 주당 83.53달러에 매각했다고 보고했습니다. 매각 후 그는 총 114,088주를 수익적으로 보유하고 있습니다. 제출서류는 그 중 34,098주가 회사의 Amended and Restated 2003 Stock Incentive Plan에 따른 제한주로 부여되었으며, 계속 고용을 조건으로 2029년 3월 6일까지의 트랜치 날짜와 주식 수를 열거한 상세한 베스팅 일정이 포함되어 있음을 밝히고 있습니다.

Formulaire USPH 4 : Christopher J. Reading, président et directeur général de U S Physical Therapy Inc (USPH), a déclaré une transaction unique le 04/09/2025, vendant 2 000 actions ordinaires de l'émetteur au prix de 83,53 $ par action. Après la vente, il détient bénéficiairement au total 114 088 actions. Le dépôt révèle que 34 098 de ces actions ont été attribuées en tant qu'actions restreintes dans le cadre de l'Amended and Restated 2003 Stock Incentive Plan de la société, avec un calendrier d'acquisition détaillé listant les dates des tranches et le nombre d'actions jusqu'au 6 mars 2029, sous réserve de la poursuite de l'emploi.

USPH Formular 4: Christopher J. Reading, Vorsitzender und CEO von U S Physical Therapy Inc (USPH), meldete am 04.09.2025 eine einzelne Transaktion, bei der er 2.000 Aktien des Stammkapitals des Emittenten zu einem Preis von 83,53 $ pro Aktie verkaufte. Nach dem Verkauf besitzt er wirtschaftlich insgesamt 114.088 Aktien. Die Einreichung gibt an, dass 34.098 dieser Aktien als Restricted Stock im Rahmen des Amended and Restated 2003 Stock Incentive Plan des Unternehmens zugeteilt wurden, mit einem detaillierten Vesting-Plan, der Tranchen-Daten und Aktienzahlen bis zum 6. März 2029 aufführt, vorbehaltlich fortgesetzter Beschäftigung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
READING CHRISTOPHER J

(Last) (First) (Middle)
1300 W SAM HOUSTON PKWY S
SUITE 300

(Street)
HOUSTON TX 77042

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
U S PHYSICAL THERAPY INC /NV [ USPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman of the Board and CEO
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/04/2025 S 2,000 D $83.53 114,088(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 34,098 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 4,152 shares on each of November 20, 2025 and March 6, 2026, 2,902 shares on each of May 20, 2026, August 20, 2026, November 20, 2026, and March 6, 2027, 2,277 shares on each of May 20, 2027, August 20, 2027, and November 20, 2027, 2,285 shares on March 6, 2028,1,265 shares on each of May 20, 2028, August 20, 2028, and November 20, 2028, and 1,275 shares on March 6, 2029, if he is an employee of the Company on those dates.
/s/ Kate Venturina, as attorney-in-fact 09/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Christopher J. Reading report on Form 4 for USPH?

He reported a sale of 2,000 shares of USPH common stock on 09/04/2025 at a price of $83.53 per share.

How many USPH shares does the reporting person beneficially own after the reported transaction?

The Form 4 states he beneficially owns 114,088 shares following the reported sale.

Are any of the reported USPH shares subject to vesting or restrictions?

Yes. The filing discloses 34,098 restricted shares granted under the company's 2003 Stock Incentive Plan with tranche vesting dates through March 6, 2029, conditioned on employment.

Was the Form 4 filed jointly or by one reporting person?

The form was filed by one reporting person (Christopher J. Reading) as indicated on the filing.

Does the Form 4 report any derivative securities or option transactions?

No. Table II shows no derivative securities transactions or holdings reported in this filing.
U S Physical Therapy

NYSE:USPH

USPH Rankings

USPH Latest News

USPH Latest SEC Filings

USPH Stock Data

1.30B
14.90M
1.97%
105.56%
4.73%
Medical Care Facilities
Services-health Services
Link
United States
HOUSTON